A Phase I/II Study for Analytic Validation of (89)Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

PURPOSE: Standard imaging for assessing osseous metastases in advanced prostate cancer remains focused on altered bone metabolism and is inadequate for diagnostic, prognostic, or predictive purposes. We performed a first-in-human phase I/II study of (89)Zr-DFO-huJ591 ((89)Zr-J591) PET/CT immunoscint...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cancer Res
Main Authors: Pandit-Taskar, Neeta, O'Donoghue, Joseph A., Durack, Jeremy C., Lyashchenko, Serge K., Cheal, Sarah M., Beylergil, Volkan, Lefkowitz, Robert A., Carrasquillo, Jorge A., Martinez, Danny F., Fung, Alex Mak, Solomon, Stephen B., Gonen, Mithat, Heller, Glenn, Loda, Massimo, Nanus, David M., Tagawa, Scott T., Feldman, Jarett L., Osborne, Joseph R., Lewis, Jason S., Reuter, Victor E., Weber, Wolfgang A., Bander, Neil H., Scher, Howard I., Larson, Steven M., Morris, Michael J.
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4668231/
https://ncbi.nlm.nih.gov/pubmed/26175541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0552
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items